Survival, Recurrence, and Follow-up Reporting
Overview
This domain covers survival analysis, patterns of recurrence, and follow-up reporting for gynecologic cancers. Key concepts: Survival metrics include overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS). Recurrence patterns vary by cancer: cervical cancer recurs locally (pelvis) or distantly (lung, liver); endometrial cancer recurs locally or distantly (lung, abdomen); ovarian cancer recurs in the peritoneum; vulvar cancer recurs locally or in groin nodes. Follow-up guidelines: history and physical exam every 3-6 months for 2-3 years, then annually; imaging as indicated; tumor markers (CA-125 for ovarian). Reporting: cancer registries collect survival data via active follow-up and linkage with vital records. Traps: confusing recurrence with second primary; ensuring accurate dates for recurrence and last contact.
Traps
Questions often test recommended follow-up intervals. A common trap is the frequency of follow-up for ovarian cancer (CA-125 every 3 months for 2 years, then less frequent). Another trap is the definition of recurrence (new evidence of disease after a disease-free interval). Also, survival reporting requires complete follow-up; loss to follow-up can bias results. Be careful with the distinction between recurrence and persistence (disease present after primary treatment).
Worked Example
A patient with ovarian cancer achieves complete remission after surgery and chemotherapy. At 18 months, CA-125 rises and imaging shows peritoneal implants. This is a recurrence. Rule of thumb: Recurrence is defined as reappearance of disease after a documented disease-free interval; persistence is disease present immediately after treatment.